Ministry result

New CBD regulatory framework published by the French Ministry of Health opens up new business opportunities for RAMM Pharma’s European operations

Content of the article

TORONTO, January 5, 2022 (GLOBE NEWSWIRE) – RAMM Pharma Corp., including its wholly owned subsidiaries, “ Society ” Where ” RAMM “) (CSE: RAMM) , a leader in cannabinoid pharmaceutical products derived from plants, welcomes the new French regulatory framework for the sale of cannabidiol (“CBD”). According to the recent announcement, France will allow the use of the whole hemp plant, including the flowers and leaves, for the industrial production of extracts by setting the limit for THC at 0.3% in extracts by bulk and end products, with no limitations for other cannabinoids. The order of the Ministry of Health, published on Friday December 31, 2021 in the Official Journal, establishes a new regulatory framework for the sale and trading of hemp extracts.

Advertising

Content of the article

The ordinance is published on the following link: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000044793213 .

More detailed coverage is available at the following link: https://www.lemonde.fr/societe/article/2021/12/31/la-france-clarifie-sa-position-sur-le-cbd-en-interdisant-la-vente-de-fleurs-et- of-hemp-leaves_6107809_3224.html .

“2022 begins with revolutionary news because it is finally clarified and opens the market for extracts and CBD in France. This opens up a scenario that has been long overdue in Europe and should produce a domino effect for other European member states to follow suit, ”said Jack Burnett, CEO of RAMM Pharma Corp.

According to the new decree, which supplements the decree of August 22, 1990, “the flowers and leaves of the varieties [Cannabis sativa L.] can be harvested, imported or used for the industrial production of extracts ”. This is a historic breakthrough for the European market because, on the one hand, it represents the full implementation of the indications derived from the position of the European Court of Justice in the famous Kanavape case and, on the other hand , it is issued by a leading member state of the Union, France, which had until now adopted a highly restrictive position on hemp and its derivatives. France is the second largest country in the EU behind Germany with a population of over 68 million people. The total value of the EU CBD market was € 1.6 billion in 2020 and is expected to reach € 8.7 billion in 2030 (EU Hemp Market Report, HIS Markit).

Advertising

Content of the article

With its 100% stake in Canapar Corp., RAMM is well positioned to become one of the largest vertically integrated cannabis companies in Europe. Canapar’s state-of-the-art extraction facility in Sicily, Italy is the largest in Europe and has been tailor-made to produce active compounds for use in pharmaceutical, wellness, food and cosmetic products from high quality from its 1000 hectares of organic products. hemp production and processing platform.

RAMM’s strategic location in Europe also offers growing distribution opportunities for RAMM’s internationally registered cannabis product portfolio manufactured at its state-of-the-art GMP certified facility in Montevideo, Uruguay, conveniently located nearby. an international airport and other export products. hubs. This 36,000 sq.ft. The facility includes dedicated cannabis and medical products laboratories, as well as packaging capacities and storage / distribution facilities.

Advertising

Content of the article

About RAMM Pharma Corp.
RAMM Pharma is a leader in cannabinoid pharmacology and product formulation for cannabis pharmaceuticals and other cannabis products with a unique and diverse international production and sales platform. The company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved cannabinoid pharmaceuticals plant-derived products that have been cleared for sale and / or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered cannabis nutritional products and specialty veterinary products, at various stages of approval and development, which are produced in state-of-the-art cannabis and certified by good manufacturing practice. formulation facility in Montevideo, Uruguay.

Advertising

Content of the article

In Europe, RAMM’s vertically integrated operations are based in Ragusa, Italy, and include: a hemp cultivation platform; a large extraction and processing facility (in final commissioning phase) to produce a wide range of cannabidiol formulations, APIs (active pharmaceutical ingredients) and wellness products.

RAMM Pharma comprises the wholly owned subsidiaries Canapar Corp., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.rammpharma.com .

For more information, please contact:

Antonio Caruso
Chief Operating Officer of Canapar, SRL
+39 331 188 5927
[email protected]

Caution regarding forward-looking information

Advertising

Content of the article

This press release contains forward-looking information and forward-looking statements (collectively, forward-looking statements ) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this press release. Any statement that involves discussions regarding predictions, expectations, beliefs, plans, projections, goals, assumptions, future events, or performance (often but not always using expressions such as “expects” , or “does not expect”, “plans” or “does not plan”, “plans”, “budget”, “planned”, “forecasts”, “estimates”, “believes” or “intention” or variations of these words and expressions or indicating that certain actions, events or results (“may” or “could”, “would”, “could” or “would” be considered as taking place or being achieved) are not statements of historical fact and may be forward-looking statements. In this press release, forward-looking statements relate, among other things, to the strategies and objectives of the Company and future expansion plans.

Advertising

Content of the article

These forward-looking statements are based on reasonable assumptions and estimates of the management of the Company at the time these statements were made. Actual future results may differ materially, as forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from the results, performance or achievements. futures expressed or implied by these forward-looking statements. These factors include, among others: the expected benefits for RAMM from the new French regulatory framework for the sale of CBD; fluctuations in general macroeconomic conditions; fluctuations in the securities markets; expectations regarding the size of the Uruguayan, Latin American and international markets for medical and recreational cannabis and changing consumption patterns; the Company’s ability to successfully achieve its business objectives; expansion plans; political and social uncertainties; failure to obtain adequate insurance to cover risks and dangers; and the presence of laws and regulations that may impose restrictions on the cultivation, production, distribution and sale of cannabis and cannabis-related products in Uruguay or abroad; and employee relations. Although the forward-looking statements contained in this press release are based on what the management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these. forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or expected. Readers should not place undue reliance on the forward-looking statements and information contained in this press release. The Company assumes no obligation to update any forward-looking statements of beliefs, opinions, projections or other factors, in the event of change, except as required by law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved of the information contained in this document.

Main logo

Advertising

comments

Postmedia is committed to maintaining a vibrant but civil discussion forum and encourages all readers to share their views on our articles. Comments may take up to an hour of moderation before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread that you follow, or if a user that you follow comments. Visit our Community rules for more information and details on how to adjust your E-mail settings.